News Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News CONTINUUS Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S. Jan 22, 2021 Posted by CONTINUUS Pharmaceuticals, Inc.
News Expanded Global Oncology, Functional and Resourcing Services Launched by Catalyst Clinical Research Jan 19, 2021
News Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes Jan 19, 2021 Posted by Sumitomo Pharma Oncology, Inc.
News EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration Jan 19, 2021
News Azzur Group is pleased to announce the appointment of Brijesh Patel to the Director of Consulting for Azzur Worcester Jan 15, 2021
News Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020 Jan 14, 2021 Posted by Veristat, LLC
News Covington Advises AIM-listed Sensyne Health on £27.5m Fundraising and Strategic Deal Jan 13, 2021
